How to improve the risk-benefit ratio of cyclosporin therapy for psoriasis.
CsA therapy for psoriasis is hampered by side-effects. Topical CsA therapy is not effective. Therefore improvement of the risk-benefit ratio must be achieved by improvement of dose-regimens, combination therapy of CsA with another therapy for psoriasis or combination therapy of CsA with a therapy that may influence the pathogenesis of the most serious side-effect(s) of CsA. It seems that only therapies that influence the pathogenesis of CsA-induced acute renal-impairment, like oral fish oil or perhaps thromboxane synthesis inhibitors, may be beneficial. However, further studies are warranted to validate these findings.
Korstanje
M J
MJ
Department of Dermatology, Academic Hospital Maastricht, The Netherlands.
D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D008727:Methotrexate / Q000627:therapeutic use; D011701:PUVA Therapy; D011565:Psoriasis / Q000188:drug therapy*; D012176:Retinoids / Q000627:therapeutic use
D012176:Retinoids; D016572:Cyclosporine; D008727:Methotrexate